Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab in Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
NCT01196390Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2011
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by National Cancer Institute. Started Feb 2011; status: completed.
02
Drugs
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01196390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01196390.